Aperio Group LLC boosted its position in Laboratory Corp. of America Holdings (NYSE:LH) by 2.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 52,287 shares of the medical research company’s stock after purchasing an additional 1,190 shares during the quarter. Aperio Group LLC’s holdings in Laboratory Corp. of America were worth $8,340,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Valeo Financial Advisors LLC acquired a new stake in Laboratory Corp. of America in the third quarter worth approximately $444,000. Cubist Systematic Strategies LLC lifted its position in Laboratory Corp. of America by 233.1% in the third quarter. Cubist Systematic Strategies LLC now owns 10,599 shares of the medical research company’s stock worth $1,600,000 after purchasing an additional 7,417 shares during the period. Tocqueville Asset Management L.P. lifted its position in Laboratory Corp. of America by 1,906.0% in the third quarter. Tocqueville Asset Management L.P. now owns 32,677 shares of the medical research company’s stock worth $4,933,000 after purchasing an additional 31,048 shares during the period. Calamos Advisors LLC lifted its position in Laboratory Corp. of America by 21.2% in the third quarter. Calamos Advisors LLC now owns 171,866 shares of the medical research company’s stock worth $25,947,000 after purchasing an additional 30,017 shares during the period. Finally, Veritas Investment Management UK Ltd lifted its position in Laboratory Corp. of America by 46.1% in the third quarter. Veritas Investment Management UK Ltd now owns 67,533 shares of the medical research company’s stock worth $10,195,000 after purchasing an additional 21,323 shares during the period. Hedge funds and other institutional investors own 90.87% of the company’s stock.

Laboratory Corp. of America Holdings (NYSE LH) opened at $168.08 on Friday. The stock has a market capitalization of $17,490.00, a price-to-earnings ratio of 13.75, a price-to-earnings-growth ratio of 1.45 and a beta of 0.92. Laboratory Corp. of America Holdings has a twelve month low of $133.65 and a twelve month high of $181.71. The company has a debt-to-equity ratio of 0.93, a current ratio of 1.31 and a quick ratio of 1.75.

Laboratory Corp. of America (NYSE:LH) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $2.45 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.38 by $0.07. The company had revenue of $2.70 billion for the quarter, compared to analysts’ expectations of $2.70 billion. Laboratory Corp. of America had a return on equity of 16.30% and a net margin of 12.15%. The firm’s revenue was up 13.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.15 earnings per share. equities research analysts forecast that Laboratory Corp. of America Holdings will post 11.52 EPS for the current fiscal year.

In other Laboratory Corp. of America news, Director Adam H. Schechter sold 1,263 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $169.29, for a total transaction of $213,813.27. Following the sale, the director now directly owns 7,297 shares of the company’s stock, valued at approximately $1,235,309.13. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.90% of the stock is owned by insiders.

A number of equities research analysts have weighed in on the company. Robert W. Baird set a $183.00 target price on Laboratory Corp. of America and gave the stock a “hold” rating in a research report on Thursday. ValuEngine cut Laboratory Corp. of America from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Craig Hallum reaffirmed a “buy” rating and issued a $204.00 price target (up previously from $180.00) on shares of Laboratory Corp. of America in a report on Wednesday. Citigroup upped their price target on Laboratory Corp. of America from $161.00 to $184.00 and gave the company a “neutral” rating in a report on Friday. Finally, Zacks Investment Research raised Laboratory Corp. of America from a “hold” rating to a “buy” rating and set a $190.00 price target on the stock in a report on Friday. Six analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $180.73.

TRADEMARK VIOLATION NOTICE: This story was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://theolympiareport.com/2018/02/11/laboratory-corp-of-america-holdings-lh-shares-bought-by-aperio-group-llc.html.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corp. of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.